Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease: pathophysiology and diagnostic aspects

European Journal of Preventive Cardiology, Год журнала: 2025, Номер unknown

Опубликована: Фев. 27, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) can be interpreted as the hepatic expression of metabolic syndrome, which is estimated to affect 30% adult population. Obesity, dyslipidaemia, arterial hypertension, and T2DM are considered significant risk factors MASLD. The relationship two-way with MASLD found in up 75% patients T2DM. Importantly, associated increased cardiovascular diseases (CVD) such arrhythmia, atherosclerotic heart disease, failure, CVD-associated mortality. In addition, present a high prevalence major adverse cardiac events, calls for systematic surveillance CVD This review focuses on pathophysiology behind development MASLD, types complications, morbidity survival, suggestions evaluation

Язык: Английский

---

Hepatitis B virus infection and metabolic dysfunction associated steatotic liver disease: Rising pandemic with complex interaction

World Journal of Hepatology, Год журнала: 2025, Номер 17(1)

Опубликована: Янв. 6, 2025

Due to sedentary lifestyle and rising prevalence of obesity, patients with general population those who are infected chronic hepatitis B found have metabolic dysfunction associated steatotic liver disease (MASLD). Both virus (HBV) infection MASLD can damage hepatocytes in their own way, but concomitant HBV-MASLD has its clinical implications. Cherry on top is the presence diabetes mellitus, hypertension or obesity which added more chances unfavorable outcomes these patients. In this article, we comment article by Wang et al published recent issue. This provides a comprehensive overview complex interaction between HBV-MASLD, HBV alone We discuss key findings from studies, including promising observed concurrent MASLD, warrants further research. The insights presented here offer renewed understanding interaction.

Язык: Английский

---

Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States

Nutrition Journal, Год журнала: 2025, Номер 24(1)

Опубликована: Янв. 14, 2025

The objective of this study was to investigate the association between sarcopenia and liver fibrosis in patients aged 18–59 years with metabolic dysfunction-associated steatotic disease (MASLD) assess potential as a risk factor for progression fibrosis. included 821 MASLD US cohort 3,405 Chinese cohort. Liver controlled attenuation parameters (CAP) stiffness measurements (LSM) were assessed by vibration-controlled transient elastography (VCTE) evaluate extent hepatic steatosis Sarcopenia measuring appendicular skeletal muscle mass (ASM) calculating ASMI. To analyze relationship sarcopenia, ASMI, fibrosis, logistic regression models, multivariate-adjusted restricted cubic spline (RCS) models employed, stratification interaction analyses. results demonstrated that exhibited markedly elevated significant advanced cirrhosis compared those without both cohorts. After adjusting confounding variables, identified an independent MASLD. A negative correlation observed ASMI severity progressive reduction associated increasing Additionally, non-linear feature evident some indicators. Subgroup analysis further corroborated finding harmful effect on consistent across all subgroups. may be Monitoring assist identifying individuals at patients.

Язык: Английский

---

From Dysbiosis to Hepatic Inflammation: A Narrative Review on the Diet-Microbiota-Liver Axis in Steatotic Liver Disease

Microorganisms, Год журнала: 2025, Номер 13(2), С. 241 - 241

Опубликована: Янв. 23, 2025

The gut microbiota has emerged as a critical player in metabolic and liver health, with its influence extending to the pathogenesis progression of steatotic diseases. This review delves into gut-liver axis, dynamic communication network linking microbiome through metabolic, immunological, inflammatory pathways. Dysbiosis, characterized by altered microbial composition, contributes significantly development hepatic steatosis, inflammation, fibrosis via mechanisms such barrier dysfunction, metabolite production, systemic inflammation. Dietary patterns, including Mediterranean diet, are highlighted for their role modulating microbiota, improving axis integrity, attenuating injury. Additionally, emerging microbiota-based interventions, fecal transplantation bacteriophage therapy, show promise therapeutic strategies disease. However, challenges population heterogeneity, methodological variability, knowledge gaps hinder translational application current findings. Addressing these barriers standardized approaches integrative research will pave way microbiota-targeted therapies mitigate global burden

Язык: Английский

---

Bile acids and their receptors in hepatic immunity

Liver Research, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Язык: Английский

---